Assessment of the Value of Nivolumab Plus Ipilimumab for Treating Microsatellite Instability-High/Mismatch Repair Deficiency Metastatic Colorectal Cancer: Indirect Treatment Comparison and Cost-Effectiveness Analysis. (PubMed, Adv Ther) - Sep 9, 2026 - P3 | "This is the first study demonstrating that first-line treatment with nivolumab plus ipilimumab may offer significant health economic benefits over pembrolizumab when used to treat first-line MSI-H/dMMR mCRC patients. With QALY gains ranging from 1.65 to 2.35 across various ITC methodologies, nivolumab plus ipilimumab seems a compelling treatment option for first-line MSI-H/dMMR mCRC."
HEOR • Journal • Mismatch repair • MSI-H • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI
|
|
Bodille P M Blomaard; Claire L Simons; Craig Bennison; Elizabeth A Sigworth; Katharina Nickel; Kiran Dave; Lixian Jin; Lytske J Bakker; Reginald Villacorta; Zoe Cheah
|